DealsMay 27, 2026, 08:02 AM
MIRA Pharma Secures Worldwide Rights for Ketamir-2, Expands IP
AI Summary
MIRA Pharmaceuticals amended its exclusive license agreement with MIRALOGX LLC for Ketamir-2, expanding its licensed territory from North America to worldwide rights in all countries with patent protection. The amendment also broadens the patent portfolio to include international filings across 10 major pharmaceutical markets. This strategic move aims to support the global development and commercialization of Ketamir-2, which is advancing towards Phase 2a development for chemotherapy-induced peripheral neuropathy (CIPN) following positive Phase 1 results.
Key Highlights
- MIRA Pharmaceuticals secured worldwide exclusive rights for Ketamir-2 from MIRALOGX LLC.
- Licensed territory expanded from the United States, Canada, and Mexico to all countries with patent rights.
- Expanded patent portfolio includes filings in 10 major markets: US, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, and South Korea.
- The amendment supports the global development and commercialization strategy for Ketamir-2.
- Ketamir-2 is advancing toward planned Phase 2a development for chemotherapy-induced peripheral neuropathy (CIPN).
- Phase 1 clinical results showed favorable safety and tolerability in 56 healthy volunteers.
- Core economic terms of the original license agreement were not materially modified.
Price Impact
More from MIRA